In veterinary medicine, antiparasitic drugs are among the most used drugs in treatments, with ivermectin being one of the representatives. This drug has as one of its characteristics the high liposolubility, which facilitates its distribution throughout the body, however, even with this high...
Author(s)
Mangolin, L. F.; Ferreira, N. de F.; Santos, A. G. dos; Caminhas, M. M. T.
Publisher
Fundacao Educacional de Ituverava, Sao Paulo, Brazil
Citation
Nucleus Animalium, 2021, 13, 1, pp 27-33
Background and Aim: Canine demodicosis is a skin disease that is a major global health problem in dogs. Ivermectin is a drug of choice for treatment, but it may cause toxicity in dogs carrying multidrug resistance mutation-1 gene mutations. Hence, alternative herbal medicines are used instead of...
Author(s)
Artchayasawat, A.; Boueroy, P.; Boonmars, T.; Pumhirunroj, B.; Sriraj, P.; Aukkanimart, R.; Boonjaraspinyo, S.; Pitaksakulrat, O.; Ratanasuwan, P.; Suwannatrai, A.; Eamudomkarn, C.; Laummaunwai, P.; Wu ZhiLiang
Publisher
Veterinary World, Wankaner, India
Citation
Veterinary World, 2021, 14, 11, pp 2919-2928
The multidrug resistance gene MDR1 (syn. ABCB1) encodes for the multidrug efflux transporter P-glycoprotein (P-gp), which is highly expressed at the blood-brain barrier and protects the brain from potentially neurotoxic compounds, such as ivermectin. MDR1 mutation in dogs is known to be linked to...
Author(s)
Nürnberger, D.; Wagner, L.; Müller, S. F.; Leiting, S.; Leidolf, R.; Alber, J.; Hamann, M.; Geyer, J.
Publisher
Frontiers Media S.A., Lausanne, Switzerland
Citation
Frontiers in Veterinary Science, 2022, 8, February,
Advocate® (2.5% moxidectin+10% imidacloprid) (Bayer HealthCare, Leverkusen, Germany) is a multiparasiticidal spot-on authorized for treating canine demodicosis in many countries. This blinded, randomized three-phase clinical trial compared its efficacy employing different dosing regimens with that...
Author(s)
Paterson, T. E.; Halliwell, R. E.; Fields, P. J.; Louw, M. L.; Ball, G.; Louw, J.; Pinckney, R.
Publisher
Elsevier B. V., Amsterdam, Netherlands
Citation
Veterinary Parasitology, 2014, 205, 3/4, pp 687-696
This case report describes ivermectin-induced blindness in a dog and a foal with normal ophthalmic fundic examinations and attenuated electroretinography (ERG). Subsequent recovery in ERG was noted following intravenous lipid emulsion (ILE) therapy. A dog and a foal were evaluated for ...
Author(s)
Pollio, D.; Michau, T. M.; Weaver, E.; Kuebelbeck, K. L.
Publisher
Wiley, Boston, USA
Citation
Veterinary Ophthalmology, 2018, 21, 1, pp 82-87
Background: A mutation in the canine multidrug resistance MDR1 gene (also referred as ABCB1), encoding for the multidrug resistance (MDR) P-glycoprotein (P-gp) transponder, causes a pathological condition known as 'ivermectin toxicosis'. The causative mutation, known since 2001, has been described...
Author(s)
Marelli, S. P.; Polli, M.; Frattini, S.; Cortellari, M.; Rizzi, R.; Crepaldi, P.
Publisher
BMJ Publishing Group, London, UK
Citation
Veterinary Record Open, 2020, 7, e000375,
Background: P-glycoprotein is a multidrug resistance (MDR) transporter, a member of the ATP binding cassette (ABC) family and is highly expressed in capillary endothelial cells in the brain. Its physiological function is to protect the body from potentially toxic compounds. In certain dog breeds a...
Author(s)
Palócz, O.; Benedek-Major, K.; Csigó, B.; Csikó, G.
Publisher
Herman Ottó Institute Nonprofit Ltd., Budapest, Hungary
Citation
Magyar Állatorvosok Lapja, 2018, 140, 8, pp 495-500
Background: Canine screw-worm myiasis due to Cochliomyia hominivorax or Chrysomya bezziana has traditionally been treated with extra-label use of ivermectin. The larvicidal activities of nitenpyram and spinosad/milbemycin also have been described, but there have been no reports to describe the...
Author(s)
Han HockSiew; Chen, C.; Schievano, C.; Noli, C.
Publisher
Wiley, Oxford, UK
Citation
Veterinary Dermatology, 2018, 29, 4, pp 312-e109
Objective: To develop in genetically engineered mice an alternative screening method for evaluation of P-glycoprotein substrate toxicosis in ivermectin-sensitive Collies. Animals: 14 wild-type C57BL/6J mice (controls) and 21 genetically engineered mice in which the abcb1a and abcb1b genes were...
Author(s)
Orzechowski, K. L.; Swain, M. D.; Robl, M. G.; Tinaza, C. A.; Swaim, H. L.; Jones, Y. L.; Myers, M. J.; Yancy, H. F.
Publisher
American Veterinary Medical Association, Schaumburg, USA
Citation
American Journal of Veterinary Research, 2012, 73, 9, pp 1477-1484
This study evaluated the impact of the ABCB1-1Δ mutation in Collies which exhibited toxicity toward ivermectin, on changes in gene expression when given the unrelated ABCB1 substrate loperamide, to identify potential biomarkers predictive of drug safety. Thirty-two healthy intact Collies consisting ...
Author(s)
Zhu, M.; Yancy, H. F.; Deaver, C.; Jones, Y. L.; Myers, M. J.
Publisher
Wiley-Blackwell, Oxford, UK
Citation
Journal of Veterinary Pharmacology and Therapeutics, 2016, 39, 2, pp 131-137